ScreenPoint Medical plans to highlight Transpara Breast AI at the upcoming ECR 2024 meeting.
The technology assists radiologists in detecting breast cancers earlier and aims to reduce recall rates. ScreenPoint will host four presentations and three posters to be presented at ECR. These include a randomized controlled trial where cancer-detection rates and the types of detected cancers were analyzed in the Mammography Screening With Artificial Intelligence (MASAI)-trial study population and a prospective clinical trial where the AI's ability to safely reduce workload by excluding low-risk cases for human reading was studied.
